Drug intelligence / Profile preview

Wei Li Bai

Development stage: Phase 2
Lead developer: Capital Medical University
Modality: Small Molecules
Administration: Oral

Overview

**Wei Li Bai** is an investigational oral fixed-dose capsule developed by Capital Medical University for mild to moderate Alzheimer's disease. The formulation contains **chrysin**, **L-rhamnose**, and **sodium ferulate**. It was evaluated in a randomized, double-blind, placebo-controlled Phase 2 study intended to assess cognitive function, activities of daily living, and symptom severity. The proposed pharmacological rationale includes metabolic regulation, improved circulation, anti-inflammatory activity, and antioxidant effects, but a specific molecular target and validated mechanism have not been publicly disclosed. The registered Phase 2 study was terminated.

Brand names: wei li bai
Other names: Wei Li BaiWei Li Bai CapsuleWei Li Bai CapsulesWei Libai Capsule

Beyond the preview

Go deeper on Wei Li Bai.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wei Li Bai.

Explore the full profile